Curium Launches First PYLCLARI® Doses in Germany for Prostate Cancer

Curium, a global leader in nuclear medicine, has announced the first commercial deliveries of PYLCLARI® in Munich and Nurnberg, Germany. PYLCLARI® (INN: Piflufolastat (18F), also known as (18F)-DCFPyL) is utilized for detecting prostate-specific membrane antigen (PSMA) positive lesions using positron emission tomography (PET) in prostate cancer patients. This diagnostic tool is applicable in two main clinical settings: primary staging for high-risk prostate cancer patients before initial curative therapy, and localization of prostate cancer recurrence in patients with suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels post primary treatment.

Benoit Woessmer, the PET Europe CEO at Curium, expressed satisfaction with the increasing availability of PYLCLARI® to more nuclear medicine professionals and their patients across Europe. He highlighted the company's pride in enhancing the diagnostic options available to patients with prostate cancer in Germany.

In Germany, prostate cancer is the most prevalent cancer among men, with about 63,400 new cases diagnosed annually. The recent delivery of PYLCLARI® is part of Curium's ongoing expansion across the European Union. The product is already accessible to prostate cancer patients in Greece, Italy, and the Netherlands.

In the United States, Lantheus received FDA approval for PYLARIFY® (Piflufolastat (18F) Injection) in May 2021, making it the leading PSMA PET agent in the U.S. market. Curium obtained the European rights to this product from Progenics, a Lantheus company, in 2018.

Curium stands out in the nuclear medicine field by developing, manufacturing, and distributing top-tier radiopharmaceutical products globally. Their extensive legacy, combined with forward-thinking strategies, ensures innovation and exceptional service. Curium operates manufacturing sites across Europe and the United States, providing SPECT, PET, and therapeutic radiopharmaceutical solutions to over 14 million patients annually. The company’s name, ‘Curium’, honors the legacy of Marie and Pierre Curie, emphasizing its dedication to nuclear medicine.